Research on the trials that test new treatments in patients. Covers trial design, respiratory and cancer trials, screening tools, and treatment breakthroughs.
A clinical trial evaluated the economic impact of adding a dedicated team to existing emergency department care for older patients. The study found that this approach can significantly improve patient quality of life and save up to €2.4 billion nationally.
A University of Otago-led trial found that extended-release ketamine tablets significantly improved depressive symptoms in adults with treatment-resistant depression. The tablets showed good tolerability and minimal side effects compared to traditional injection or nasal spray methods.
The ARMMS-T2D study found that bariatric surgery yields greater long-term improvements in quality-of-life compared to medical management, with sustained weight loss correlating with better health and reduced pain.
A new ketamine tablet form has shown promise in treating severe depression with negligible side effects and convenience. The study found that patients on the strongest dose of ketamine had the best results compared to placebo.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
A randomized clinical trial found that an intermittent fasting plan consisting of two nonconsecutive fasting days and five days of meal replacement diet improved glycemic outcomes and weight loss in the short term compared to metformin or empagliflozin. The study suggests a promising initial intervention for type 2 diabetes management.
Researchers found that adding an anti-inflammatory drug to immune checkpoint inhibitor therapy resulted in a high response rate of 67% among patients with stage 4 non-small cell lung cancer. The study suggests that reducing chronic inflammation may improve the effectiveness of immunotherapy.
A preliminary clinical trial found that nicotinamide riboside, a form of vitamin B3, increased the walking endurance of patients with peripheral artery disease by over 57 feet. The study suggests that nicotinamide riboside may be a new option for treating chronic leg disease.
A subset of patients with stage 3 colon cancer who have PIK3CA mutations may benefit from celecoxib treatment, which improved overall survival and reduced disease-free survival rates. The study's findings suggest a potential personalized approach to additional therapy for patients with early-stage colon cancer.
A randomized clinical trial found that both electronic cigarettes containing nicotine and varenicline were effective for 6-month smoking cessation. The study results suggest a potential new approach to smoking cessation.
Researchers at Mass General Brigham developed a generative AI process that screens patients for clinical trial eligibility with high accuracy and reduced cost. The process, called RECTIFIER, was compared to traditional screening methods and found to be more accurate and cost-effective, with an estimated cost of $0.11 per patient.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
A multicenter randomized trial identified a noninvasive ventilation method as effective in reducing the risk of hypoxemia and cardiac arrest during emergency tracheal intubation. The study found that this method cut the risk of hypoxemia in half and drastically reduced the risk of cardiac arrest compared to oxygen mask preoxygenation.
A phase II clinical trial found trametinib effective in treating pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML), with seven of ten patients alive after two years. The treatment showed antitumor activity and downregulated inflammatory signaling, offering hope for JMML patients and their families.
A new study found that a liberal blood transfusion strategy may improve outcomes for patients with traumatic brain injury, leading to better functional independence and quality of life. Six months after the injury, patients who received more frequent blood transfusions showed higher levels of recovery and improved quality of life compa...
Researchers have developed a study using smartwatches to monitor Parkinson's symptoms over time in early-stage patients. The study found significant declines in gait and tremor, as well as changes in speech, with the smartwatch detecting these changes more effectively than traditional tools.
The BLING III trial found a 2% lower 90-day mortality and a 6% higher clinical cure rate for continuous β-lactam antibiotic infusions compared to intermittent infusions in critically ill patients with sepsis. Continuous infusions were also associated with improved patient outcomes.
The Pennington Biomedical Research Center is conducting a clinical trial to better understand lipedema. Participants will undergo comprehensive assessments and imaging techniques to help advance medical knowledge related to chronic disease. Compensation of up to $475 is offered for participation in the three-month study.
A clinical trial shows that a combination of injectable naltrexone and extended-release oral bupropion reduces methamphetamine use for up to 12 weeks. The study found a significant increase in methamphetamine-negative urine tests among participants receiving the two-drug therapy.
A 15-day course of nirmatrelvir-ritonavir did not demonstrate a significant improvement in select postacute sequelae of SARS-CoV-2 infection symptoms in vaccinated adults with prolonged symptom duration. Further studies are needed to determine the role of antivirals in PASC treatment.
The NIH is investing $30 million in a pilot program called CARE for Health, which aims to integrate clinical research with community-based primary care. The initiative seeks to improve health outcomes by providing access to clinical research and expanding opportunities for participation in clinical trials.
A novel combination of oncolytic virus and immune checkpoint inhibitor has shown remarkable efficacy in treating non-muscle invasive bladder cancer, with a complete response rate of 57.1% at 12 months. The therapy demonstrated durable responses, with a median duration of response not yet reached after a median follow-up of 26.5 months.
A lifesaving package of interventions to objectively identify and treat post-partum haemorrhage (PPH) has been found to be highly cost-effective, incurring minimal additional cost. The intervention resulted in over 1000 fewer PPH cases compared to usual care, with an estimated average additional cost of $0.30 per patient.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
A clinical trial discovered that the drug abrocitinib, approved for eczema treatment, significantly reduced symptoms of patients with severe itching diseases. Abrocitinib improved symptoms in both prurigo nodularis and chronic pruritus of unknown origin by 78% and 54%, respectively.
A novel gene therapy has restored hearing function in five children with DFNB9 who were treated in both ears, demonstrating additional benefits compared to a previous trial. The treatment also improved speech perception and sound localization abilities, including the ability to appreciate music.
A study by researchers at the University of Arizona found that veterans paired with service dogs for three months had significantly lower self-reported PTSD symptom severity, anxiety, depression, and feelings of isolation. They also experienced a 66% lower odds of receiving a PTSD diagnosis.
Two mid-stage studies assess lenacapavir's safety and acceptability in cisgender women and people who inject drugs, adding to a global manufacturer-led clinical development program. The trials aim to provide insights on how these priority populations experience long-acting HIV PrEP.
The NRG-RTOG 0848 clinical study found that adding chemoradiation to adjuvant systemic therapy improves overall survival for node-negative pancreatic cancer patients, but not for those with node-positive disease. Disease-free survival was also improved in both groups.
Patients with intracerebral hemorrhage have better medical outcomes when surgeons perform early minimally invasive removal of a hematoma compared to standard care. The study found improved survival rates and functional outcomes at 180 days for patients who received early surgical intervention.
A recent study published in JAMA Cardiology found that dual direct-current cardioversion is significantly more effective than single cardioversion in restoring sinus rhythm in obese patients with atrial fibrillation. The study demonstrated a 98% success rate for dual cardioversion, compared to an 86% success rate for single cardioversion.
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.
The article discusses the need for better integration of clinical trials and health care delivery enterprises to improve patient safety and healthcare outcomes. The study highlights the benefits of integrating clinical trials with medical practice, including more accurate diagnosis and treatment of patients.
A study from Michigan Medicine reveals a connection between neutrophil activation and severe cytokine release syndrome (CRS), a potentially life-threatening reaction to CAR T-Cell therapy. Researchers identified biomarkers of NETosis, a process in which neutrophils create webs that may contribute to CRS.
A combination of amivantamab and lazertinib shows benefits over standard treatment in a subgroup of patients with advanced lung cancer, particularly those with poor prognostic markers. The new therapeutic strategy reduced the risk of disease progression and death by 30% compared to osimertinib.
The NADINA trial found that 59% of patients responded well to neoadjuvant immunotherapy before surgery, allowing them to forgo adjuvant treatment. This treatment approach also showed rapid effects, with 95% of patients remaining tumor-free after just six weeks.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers at Texas A&M University developed vessel-chip technology to create a platform for preclinical drug discovery, reducing the need for animal testing. The system mimics human circulatory systems using tissue-engineered microfluidic devices.
Patients who received COVID-19 vaccines after acute coronary syndromes had similar rates of primary composite end point and major adverse cardiovascular events (MACE) compared to unvaccinated patients. Retrospective studies have shown a short-term reduction in MACE risk after COVID-19 vaccination.
The study reveals that fear of harming fetus is a significant barrier to participation, while also highlighting importance of culturally sensitive recruitment strategies. Factors such as lack of trust in research institutions, limited access to healthcare, and social norms also play crucial role in shaping participation rates.
Researchers from Mass General Cancer Center are set to present key findings on palliative care delivery via telehealth versus in-person for patients with advanced lung cancer. The presentations also cover advances in colorectal and breast cancer treatments, as well as results from a phase 1b/2 study on a novel BRAF inhibitor.
A clinical trial led by Mount Sinai researchers shows zodasiran, an RNA inhibitor targeting ANGPTL3, significantly reduces various types of cholesterol and triglycerides. The therapy also lowers apolipoprotein B, a lipid-transporting protein linked to heart disease.
Researchers from Ben-Gurion University of the Negev have discovered a link between proteomic biomarkers and liver fat percentage, which may improve patient monitoring and therapy targeting for NAFLD. The study, conducted over 18 months, found that specific protein changes were independently associated with liver fat relative change.
The SELECT Trial found semaglutide to significantly reduce the risk of kidney-related complications and improve kidney function in individuals with overweight or obesity and cardiovascular disease. The study revealed that semaglutide's ability to prevent macroalbuminuria was a key factor in reducing kidney-related events.
A groundbreaking study reveals semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. Semaglutide also shows improved safety and efficacy profiles.
SWOG Cancer Research Network will share results of their work in 30 presentations at the 2024 American Society of Clinical Oncology Annual Meeting, May 31 – June 4 in Chicago. The research focuses on improving cancer treatments and reducing devastating side effects.
Researchers from Penn Medicine's Abramson Cancer Center and Perelman School of Medicine will present results from clinical trials for esophageal cancer, CAR T cell therapy, and ovarian cancer. The meeting will feature more than 200 sessions on AI in cancer care.
A cluster randomized trial found that at-school HPV vaccination significantly increased vaccination coverage, but training general practitioners and education had limited impact. The study aimed to assess the effectiveness of a school- and primary care-based HPV vaccination intervention.
A new study at the University of Copenhagen reveals that urolithin A, a naturally occurring substance in pomegranates, can alleviate memory problems and other consequences of dementia. The substance shows promise in improving brain function by removing damaged mitochondria.
The FDA committee voted unanimously to approve minimal residual disease (MRD) as a new clinical endpoint for evaluating proposed drugs to treat multiple myeloma. A meta-analysis led by C. Ola Landgren shows a strong correlation between MRD and clinical outcomes in newly diagnosed and relapsed patients.
The conference will feature 12 late-breaking clinical trials and science presentations on transcatheter aortic valve replacement, mitral and tricuspid devices and techniques. Data from these trials will guide the selection of patients who will benefit most from procedures and define optimal treatment strategies.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
Researchers report that dupilumab substantially decreases exacerbation frequency and improves lung function as well as symptom burden in COPD patients with type 2 inflammation. The study's findings are promising for these patients, who have a high risk of exacerbations.
A new study at Hebrew University found that guided internet-based cognitive behavioral therapy significantly improves depression and insomnia symptoms over time. The study emphasizes the importance of the therapeutic alliance and attachment styles in predicting treatment outcomes.
Research found that race-neutral spirometry equations tend to decrease severity for white patients and increase severity for Black patients, leading to higher enrollment rates of Black patients in COPD clinical trials. This shift resulted in more Black subjects meeting typical inclusion criteria, while fewer white subjects were eligible.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A web-based cognitive behavioral self-help intervention has been shown to effectively reduce binge eating episodes and improve various mental health outcomes in patients with binge eating disorder. This scalable solution bridges the treatment gap for this condition, offering a promising alternative to traditional therapies.
A study published in Circulation found that revascularization significantly enhances the health-related quality of life (HRQoL) for patients with chronic limb-threatening ischemia. Patients who underwent endovascular intervention (Endo) showed slight statistical superiority over those who received surgical bypass (Bypass) in some HRQoL...